Your session is about to expire
← Back to Search
Accelerated TMS for Depression and OCD
Study Summary
This trial will test a new accelerated 5-day rTMS protocol for treating symptoms of depression and OCD. The goal is to improve symptoms and identify biomarkers for depression and OCD.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am not on antidepressants or have been on a stable dose for 4+ weeks.I have a history of seizures or take medication that could increase my risk of seizures.I do not have symptoms that would affect my understanding of the trial.I am able to understand and agree to the study's procedures and risks.I started psychotherapy within the last 8 weeks.You are currently at a high risk of harming yourself or having thoughts of suicide.I have not had serious brain injuries, strokes, Parkinson's, or similar conditions.I have been diagnosed with major depression or OCD.You have had a significant problem with drugs or alcohol in the past 6 months.I have been diagnosed with major depression or OCD.You have mental health conditions other than OCD, depression (MDD), and anxiety (GAD) that are being studied in this trial. Examples include PTSD, severe depression with hallucinations, bipolar disorder type I or II, and primary psychotic illness.You have significant symptoms of depression or obsessive-compulsive disorder based on a standardized test.My current depression treatment hasn't worked despite proper dosage and time.You have a high level of depression or obsessive-compulsive symptoms based on two rating scales.
- Group 1: OCD - DMPFC target to (for non-responders) LPFC target
- Group 2: OCD - LPFC target to (for non-responders) DMPFC target
- Group 3: Depression - LPFC target to (for non-responders) DMPFC target
- Group 4: Depression - DMPFC target to (for non-responders) LPFC target
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: You will receive the treatment for 5 null
- Follow Ups: You may be asked to continue sharing information regarding the trial for 8 Weeks after you stop receiving the treatment.
Frequently Asked Questions
What is the sample size of this research study?
"Yes, according to clinicaltrials.gov this medical research is presently recruiting patients. Initially posted on August 18th 2021 and last edited June 27th 2022, the study seeks 300 participants at a single site."
What are the eligibility requirements for participation in this research project?
"This clinical trial, which is open to adults aged 18-70 with depression and OCD, seeks 300 participants. The necessary criteria for enrolment include a failure of current treatment despite adequate dosing; DSM-V diagnosis of major depressions disorder or obsessive compulsive disorder; Hamilton Depression Rating Scale score greater than 18 OR Yale-Brown Obsessive Compulsive Scale score higher than 16; stable dose of antidepressants for at least 4 weeks with plans to remain on this dosage during the study; and capacity to give informed consent."
Does this trial accept senior citizens as participants?
"This medical trial is open to patients who are 18 years or older, but not yet 70."
Are there still opportunities available to participate in this medical experiment?
"Per the clinicaltrials.gov registry, this research is actively recruiting patient populations; the study was first advertised on August 18th 2021 and underwent its latest update June 27th 2022."
What are the key objectives of this experimental procedure?
"Over the Baseline to Treatment End: Day 5, 10, 15 or 20 (depending on number of courses administered) period for this trial, investigators will assess the Percent Change in Yale-Brown Obsessive Compulsive Scale scores. Additionally, they shall measure the change in Beck Anxiety Inventory results (ranging from 0 - 63), General Anxiety Disorder rankings (from 0 - 21), and resting-state fMRI connectivity between frontostriatal network and limbic network (between 0 - 1)."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
What questions have other patients asked about this trial?
Why did patients apply to this trial?
How responsive is this trial?
Typically responds via
Share this study with friends
Copy Link
Messenger